Neumora Therapeutics (NMRA) Gains from Investment Securities (2022 - 2026)
Neumora Therapeutics' quarterly Gains from Investment Securities came in at $32.4 million in Q1 2026, up 37827.91% quarter-over-quarter from -$86000.0 in Q4 2025.
Neumora Therapeutics has reported Gains from Investment Securities for 5 years, with the latest figure at $32.4 million in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities changed N/A year-over-year to $32.4 million; the trailing twelve-month figure through Mar 2026 stood at $32.4 million (up 14921.3% YoY), and the FY2025 full-year result was $23.4 million, up 68.33% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $32.4 million, up from -$86000.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $32.4 million in Q1 2026, with the low at -$298000.0 in Q4 2022.
- Average Gains from Investment Securities over 5 years is $4.3 million, with a median of $391903.0 recorded in 2023.
- Peak annual rise in Gains from Investment Securities reached 5993.33% in 2024, while the deepest fall reached 8.28% in 2024.
- Tracing NMRA's Gains from Investment Securities over 5 years: stood at -$298000.0 in 2022, then soared by 182.55% to $246000.0 in 2023, then soared by 68.29% to $414000.0 in 2024, then slumped by 120.77% to -$86000.0 in 2025, then surged by 37827.91% to $32.4 million in 2026.
- The last three Gains from Investment Securities figures came in at $32.4 million (Q1 2026), -$86000.0 (Q4 2025), and $13.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Neumora Therapeutics | 328.27 Mn | 328.27 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.45 Mn |
| Mar 31, 2026 | 32.45 Mn |
| Dec 31, 2025 | -86,000.00 |
| Dec 31, 2025 | -86,000.00 |
| Sep 30, 2025 | 13.61 Mn |
| Sep 30, 2025 | 13.61 Mn |
| Jun 30, 2025 | 3.44 Mn |
| Jun 30, 2025 | 3.44 Mn |
| Sep 30, 2024 | 414,000.00 |
| Sep 30, 2024 | 414,000.00 |
| Jun 30, 2024 | 401,462.00 |
| Jun 30, 2024 | 401,462.00 |
| Mar 31, 2024 | 884,000.00 |
| Mar 31, 2024 | 884,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Dec 31, 2023 | 246,000.00 |
| Sep 30, 2023 | 382,344.00 |
| Sep 30, 2023 | 382,344.00 |
| Jun 30, 2023 | -30,000.00 |
| Jun 30, 2023 | -30,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Mar 31, 2023 | -15,000.00 |
| Dec 31, 2022 | -298,000.00 |
| Dec 31, 2022 | -298,000.00 |